|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Harpoon Therapeutics, Inc. (HARP) |
|
|
$0.89 0.00 (0.00%) as of 4:30 Fri 9/1
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
32,670,000 |
Market
Cap: |
29.20(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.6295 - $1.06 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Harpoon Therapeutics is a clinical-stage immunotherapy company. Co.'s Tri-specific T cell Activating Construct (TriTACs) product candidates include: HPN328, which is for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217, which is for the treatment of multiple myeloma; and HPN536, which is for the treatment of ovarian and pancreatic cancers and other mesothelin- expressing solid tumors. Co.'s proprietary TriTAC product candidate is HPN601, which targets the epithelial cell adhesion molecule and is being developed for the treatment of multiple solid tumor indications.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
21,397,205 |
24,484,205 |
24,494,205 |
Total Buy Value |
$0 |
$492,135,715 |
$492,135,715 |
$502,135,715 |
Total People Bought |
0 |
1 |
3 |
3 |
Total Buy Transactions |
0 |
1 |
4 |
5 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Erbez Georgia |
Chief Financial Officer |
|
2021-09-22 |
4 |
B |
$8.10 |
$83,430 |
I/I |
10,300 |
19,215 |
1.99 |
-39% |
|
Wesche Holger |
Chief Scientific Officer |
|
2021-07-01 |
4 |
AS |
$14.00 |
$140,000 |
D/D |
(10,000) |
52,852 |
|
-51% |
|
Wesche Holger |
Chief Scientific Officer |
|
2021-07-01 |
4 |
OE |
$0.60 |
$6,000 |
D/D |
10,000 |
62,852 |
|
- |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-06-02 |
4 |
AS |
$20.50 |
$514,919 |
I/I |
(25,118) |
6,328,095 |
|
-67% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-06-01 |
4 |
AS |
$20.44 |
$377,956 |
I/I |
(18,491) |
6,353,213 |
|
-65% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-05-28 |
4 |
AS |
$20.88 |
$293,315 |
I/I |
(13,885) |
6,371,704 |
|
-65% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-05-27 |
4 |
AS |
$20.26 |
$282,850 |
I/I |
(13,961) |
6,385,589 |
|
-63% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-05-26 |
4 |
AS |
$20.04 |
$64,088 |
I/I |
(3,198) |
6,399,550 |
|
-63% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-05-24 |
4 |
AS |
$20.12 |
$100,600 |
I/I |
(5,000) |
6,402,748 |
|
-59% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-05-21 |
4 |
AS |
$20.21 |
$220,430 |
I/I |
(10,907) |
6,407,748 |
|
-61% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-05-20 |
4 |
AS |
$20.34 |
$238,242 |
I/I |
(11,713) |
6,418,655 |
|
-61% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-05-19 |
4 |
AS |
$20.39 |
$363,615 |
I/I |
(17,833) |
6,430,368 |
|
-60% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-05-18 |
4 |
AS |
$20.67 |
$380,369 |
I/I |
(18,402) |
6,448,201 |
|
-61% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-05-17 |
4 |
AS |
$20.07 |
$93,647 |
I/I |
(4,666) |
6,466,603 |
|
-60% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-05-14 |
4 |
AS |
$20.04 |
$138,276 |
I/I |
(6,900) |
6,471,269 |
|
-57% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-05-13 |
4 |
AS |
$20.06 |
$97,391 |
I/I |
(4,855) |
6,478,169 |
|
-59% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-05-12 |
4 |
AS |
$20.53 |
$609,413 |
I/I |
(29,684) |
6,483,024 |
|
-58% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-05-11 |
4 |
AS |
$20.96 |
$453,707 |
I/I |
(21,445) |
6,512,708 |
|
-59% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-05-10 |
4 |
AS |
$21.78 |
$373,436 |
I/I |
(17,133) |
6,534,153 |
|
-60% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-05-05 |
4 |
AS |
$22.52 |
$229,107 |
I/I |
(10,172) |
6,551,286 |
|
-62% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-05-04 |
4 |
AS |
$23.03 |
$685,732 |
I/I |
(29,730) |
6,561,458 |
|
-63% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-05-03 |
4 |
AS |
$23.03 |
$710,389 |
I/I |
(30,766) |
6,591,188 |
|
-62% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-04-30 |
4 |
AS |
$22.35 |
$5,990,314 |
I/I |
(268,023) |
6,621,954 |
|
-60% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-04-29 |
4 |
AS |
$22.02 |
$1,493,096 |
I/I |
(67,292) |
6,889,977 |
|
-60% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-04-28 |
4 |
AS |
$21.64 |
$1,117,733 |
I/I |
(51,022) |
6,957,269 |
|
-59% |
|
213 Records found
|
|
Page 3 of 9 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|